Impetis Biosciences Profile
Key Indicators
- Authorised Capital ₹ 4.90 Cr
as on 23-10-2024
- Paid Up Capital ₹ 3.73 Cr
as on 23-10-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 2031.10%
(FY 2023)
- Profit 465.68%
(FY 2023)
- Ebitda 1384.09%
(FY 2023)
- Net Worth 26.71%
(FY 2023)
- Total Assets 29.26%
(FY 2023)
About Impetis Biosciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.90 Cr and a paid-up capital of Rs 3.73 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kanwar Jamwal, Sriram Sethuraman, Attreyi Mukherjee, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PLC295474
- Company No.
295474
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
29 May 2017
- Date of AGM
21 Jun 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Impetis Biosciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sriram Sethuraman  | Director | 29-May-2017 | Current |
| Attreyi Mukherjee | Director | 30-Jul-2020 | Current |
| Kanwar Jamwal | Director | 29-May-2017 | Current |
| Abhishek Jain | Director | 12-Mar-2024 | Current |
Financial Performance and Corporate Structure Insights of Impetis Biosciences.
Impetis Biosciences Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 2031.1% increase. The company also saw a substantial improvement in profitability, with a 465.68% increase in profit. The company's net worth Soared by an impressive increase of 26.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Impetis Biosciences?
In 2023, Impetis Biosciences had a promoter holding of 78.84% and a public holding of 21.16%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Impetis Biosciences?
Impetis Biosciences has a workforce of 2 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Impetis Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Impetis Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
